Sobi's Niche Distribution Platform No Longer For Sale
Sobi's new CEO Guido Oelkers has decided the company's Partner Products business is to remain an integral part of its business model.
You may also be interested in...
Swedish rare diseases specialist Sobi has reported strong financials and the acquisition of a rare disease candidate on the verge of US approval. Could partner Sanofi pop the question soon?
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.